Just caught Alpha Teknova's latest earnings and the alpha symbol TKNO is showing some improvement. The company posted a Q4 loss of $4.76 million, which is actually better than the $5.72 million loss they reported last year. That's a meaningful improvement if you ask me.

What caught my attention more was the revenue side - they managed to push revenue up to $9.98 million, a solid 7.7% jump from $9.27 million in the prior year period. The EPS also tightened from negative $0.11 to negative $0.09, so there's some positive momentum in the alpha symbol's fundamentals.

Still operating at a loss, but the trajectory is what matters. Revenue growth combined with shrinking losses suggests the company's operational efficiency is heading in the right direction. Worth keeping on the radar if you follow biotech plays.